攜程(09961.HK)逆市升逾4% 業績強勁獲大行上調目標價
攜程-S(09961.HK)股價受追捧,股價曾最高見373元,現報372.2元,升4.7%,為表現最好藍籌股,成交159萬股,涉資5.8億元。攜程(TCOM.US)隔晚升6.6%。
攜程早前公布去年純利按年增逾6倍至99.18億人民幣(下同),營收按年升1.2倍至445.62億幣。期內,經調整EBITDA按年升5.5倍至139.75億元;經調整EBITDA利潤率達31%,遠超2022年僅11%。富瑞昨發表報告升攜程目標價5.7%至479港元,重申「買入」評級,以反映公司去年末季業績勝預期。
瑞銀升攜程目標價則由376元升至408元,維持「買入」評級,以反映公司今年增長前景穩固。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.